Rhinitis Clinical Trial
Official title:
A Randomised, Double Blind Placebo Controlled, 2 Way Cross Over Study in Adults With Non-allergic Rhinits to Evaluate the Effect of Once Daily Administration of Intranasal SB-705498 12mg for Two Weeks and the Response to a Chamber Challenge of Cold Dry Air
The purpose of this study is to assess the pharmacodynamic (PD) effects (Total Symptom Score
(TSS) and its individual components: rhinorrhoea, nasal congestion, post-nasal drip) of
intranasal, repeat dose SB-705498 in non-allergic rhinitis (NAR) patients elicited by a cold
dry air challenge in an environmental exposure chamber (EEC). SB-705498 is a selective
antagonist of the transient receptor potential vanilloid-1 (TRPV1) ligand gated ion channel.
TRPV1 is a cation permeable ion channel that can be activated by several physiological
factors, such as heat, protons (pH), osmotic stress, eicosanoid derivatives, anandamide, and
by products of inflammation, such as histamine, prostaglandins and bradykinin. In the nose,
the local TRPV1 expressing sensory C-fibres are thought to play a key role in the development
of nasal hyper-responsiveness to environmental provocateurs. It has been proposed that
blocking the nasal sensory nerve stimulation may control nasal hyper-responsiveness and
therefore prevent the induction of rhinitis symptoms. In this context, preclinical evidence
supports that targeting TRPV1 by SB-705498 may be an attractive option.
In this study NAR patients will be randomised, in a double blind, placebo controlled cross
over design to receive 14 day repeat doses of 12mg intra-nasal SB-705498 once daily. Whilst
dosing at home, subjects will record symptom scores to document their symptoms. In addition,
during visits to the clinical unit, acoustic rhinometry, quality of life questionnaires and
safety assessments will be monitored.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02340130 -
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
|
Phase 2 | |
| Completed |
NCT02360072 -
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
|
||
| Completed |
NCT01118312 -
Study of Asthma and Nasal Steroids
|
Phase 4 | |
| Completed |
NCT00762567 -
Phenylephrine Pediatric Pharmacokinetic Study
|
Phase 1 | |
| Completed |
NCT00541255 -
A Long-Term Examination of Asthma From Childhood Through Adolescence
|
||
| Completed |
NCT00279916 -
Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays
|
Phase 3 | |
| Completed |
NCT00524836 -
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00963573 -
Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)
|
Phase 4 | |
| Completed |
NCT00521131 -
Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites
|
Phase 4 | |
| Completed |
NCT04132570 -
A Study of Intranasal Budesonide Aqueous Spray for Treatment of Rhinitis During Periods of High Airborne Pollution
|
Phase 4 | |
| Completed |
NCT02784262 -
Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis
|
Phase 2 | |
| Terminated |
NCT02630472 -
Topical Irrigation Therapy for CRS
|
Phase 1/Phase 2 | |
| Completed |
NCT02596321 -
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
|
Phase 3 | |
| Completed |
NCT02279706 -
Korean Linguistic Adaptation of Rhinitis Controlled Assessment Test
|
N/A | |
| Completed |
NCT01971086 -
Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary
|
N/A | |
| Completed |
NCT01771120 -
Control and Burden of Asthma and Rhinitis
|
N/A | |
| Withdrawn |
NCT01177852 -
Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
|
Phase 3 | |
| Completed |
NCT01469234 -
A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)
|
Phase 4 | |
| Completed |
NCT02879929 -
Development and Validity of the DyNaChron Questionnaire for Chronic Nasal Dysfunction
|
N/A | |
| Completed |
NCT00724698 -
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
|